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ANOVA model for network meta-analysis of
diagnostic test accuracy data
Victoria Nyaga1,2, Marc Aerts2 and Marc Arbyn1
Abstract
Network meta-analysis (NMA) allow combining efficacy information from multiple
comparisons from trials assessing different therapeutic interventions for a given
disease and to estimate unobserved comparisons from a network of observed
comparisons. Applying NMA on diagnostic accuracy studies is a statistical challenge
given the inherent correlation of sensitivity and specificity.
A conceptually simple and novel hierarchical arm-based (AB) model which expresses
the logit transformed sensitivity and specificity as sum of fixed effects for test,
correlated study-effects and a random error associated with various tests evaluated in
given study is proposed. We apply the model to previously published meta-analyses
assessing the accuracy of diverse cytological and molecular tests used to triage
women with minor cervical lesions to detect cervical precancer and the results
compared with those from the contrast-based (CB) model which expresses the linear
predictor as a contrast to a comparator test.
The proposed AB model is more appealing than the CB model in that it yields the
marginal means which are easily interpreted and makes use of all available data and
easily accommodates more general variance-covariance matrix structures.
Keywords
meta-analysis, network meta-analysis, diagnostic test accuracy, hierarchical model,
ANOVA
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Introduction
Network meta-analyses (NMA) have classically been used to extend conventional
pairwise meta-analyses by combining and summarizing direct and indirect evidence
on multiple ‘therapeutic’ interventions for a given condition when the set of evaluated
interventions/treatments differs among studies. By borrowing strength from the indirect
evidence, there is a potential gain in precision of the estimates1. Furthermore, the
estimates may be less biased and more robust. Such an approach uses the data efficiently
and is line with the principle of intention-to-treat (ITT)2 in randomized clinical trials
which requires that all valid available data should be used even when a part of the data is
missing.
In a diagnostic test accuracy study, an index test and possibly one or more comparator
tests are administered to each tested subject. A standard or reference test or procedure
is also applied to all the patients to classify them as having the target condition or
not. The patients results are then categorized by the index and reference test as true
positive, false positive, true negative and false negative. The diagnostic accuracy of
the index test is represented as a bivariate outcome and is typically expressed as
sensitivity and specificity at a defined test cutoff. Differences due to chance, design,
conduct, patients/participants, interventions, tests and reference test imply there will
be heterogeneity often in opposite direction for the two typical accuracy outcomes:
sensitivity and specificity. While traditional meta-analyses allow for comparison between
two tests, there are often multiple tests for the diagnosis of a particular disease outcome.
To present the overall picture, inference about all the tests for the same condition and
patient characteristics is therefore required. The simultaneous analysis of the variability
in the accuracy of multiple tests within and between studies may be approached through
a network meta-analysis.
In combining univariate summaries from studies where the set of tests differs among
studies two types of linear mixed models have been proposed. The majority of network
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meta-analyses express treatment effects in each study as a contrast relative to a baseline
treatment in the respective study1;3. This is the so called contrast-based (CB) model.
Inspired by the CB models developed for interventional studies, Menten and Lesaffre
(2015)4 introduced a CB model for diagnostic test accuracy data to estimate the average
log odds ratio for sensitivity and specificity of the index test relative to a baseline or
comparator test.
The second type of models is the classical two-way ANOVA model with random
effects for study and fixed effect for tests5–7, the so called arm-based (AB) model.
The AB model is based on the assumption that the missing arms or tests are missing
at random. While the two types of models yield similar results for the contrasts with
restricted maximum likelihood (REML) procedures, the CB model is generally not
invariant to changes in the baseline test in a subset of studies and yields an odds ratio
(OR) making it difficult to recover information on the absolute diagnostic accuracy
(the marginal means), relative sensitivity or specificity of a test compared to another or
differences in accuracy between tests, measures that are easily interpretable and often
used in clinical epidemiology. It is common knowledge that the OR is only a good
approximation of relative sensitivity/specificity when the outcome is rare but this is
often not the case in diagnostic studies. Moreover, the AB model is simpler when the
baseline/comparator treatment varies from one study to another or when the number of
tests varies substantially among studies. By accommodating more complex variance-
covariance structures AB models have been shown to be superior to CB models8.
We apply the two-way ANOVA model in a diagnostic data setting by extending the
AB model in two ways: 1. using two independent binomial distributions to describe
the distribution of true positives and true negatives among the diseased and the healthy
individuals, 2. inducing a correlation between sensitivity and specificity by introducing
correlated and shared study effects. The resulting generalized linear mixed model is
analogous to randomized trials with complete block designs or repeated measures in
analysis of variance models where studies are equivalent to blocks. The main assumption
is that, results missing for some tests and studies are missing at random. This approach is
efficient because the correlation structure allows the model to borrow information from
the ‘imputed’ missing data to obtain adjusted sensitivity and specificity estimates for all
the tests.
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Motivating dataset
To illustrate the use of the proposed model in network meta-analysis of diagnostic test
accuracy data, we analyse data on a diversity of cytological or molecular tests to triage
women with equivocal or mildly abnormal cervical cells9–13. A Pap smear is a screening
test used to detect cervical precancer. When abnormalities in the Pap smear are not
high grade, a triage test is needed to identify the women who need referral for further
diagnostic work-up. There are several triage options, such as repetition of the Pap smear
or HPV DNA or RNA assays. HPV is the virus causing cervical cancer14. Several other
markers can be used for triage as well, such as p16 or the combinations of p16/Ki67
which are protein markers indicative for a transforming HPV infection12;15 .
The data are derived from a comprehensive series of meta-analyses on the accuracy
of triage with HPV assays, cervical cytology or molecular markers applied on
cervical specimens in women with minor cervical abnormalities9–13. Two patient
groups with minor cytological abnormalities were distinguished: women with ASC-US
(atypical squamous cells of unspecified significance) and LSIL (low-grade squamous
intraepithelial lesions). Studies were included in the analysis if they performed besides
one or more triage test a verification with a reference standard based on colposcopy and
biopsies.
In total, the accuracy of 11 tests for detecting cervical precancer were evaluated.
Labelled 1 to 11 the tests were: hrHPV DNA testing with HC2 (HC2), Conventional
Cytology (CC), Liquid-Based Cytology (LBC), generic PCRs targeting hrHPV DNA
(PCR) and commercially available PCR-based hrHPV DNA assays such as: Abbott
RT PCR hrHPV, Linear Array, and Cobas-4800; assays detecting mRNA transcripts of
five (HPV Proofer) or fourteen (APTIMA) HPV types HPV types; and protein markers
identified by cytoimmunochestry such as: p16 and p16/Ki67, which are over-expressed
as a consequence of HPV infection. Two levels of precancer (disease) were considered:
intraepithelial neoplasia lesion of grade two or worse (CIN2+) or of grade three or worse
(CIN3+). 125 studies with at least one test and maximum of six tests were included
allowing assessment of the accuracy of the eleven triage tests. In
The size of the nodes in figure 1 is proportional to the number of studies evaluating a
test and thickness of the lines between the nodes is proportional to the number of direct
comparisons between tests. The size of the node and the amount of information in a
node consequently influence the standard errors of the marginal means and the relative
measures. From the network plot, test 1 (HC2) and test 11 (APTIMA) were the most
commonly assessed tests. The network in figure 1 is connected.
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Figure 1. Network plot of all included tests1 by triage2 group (women with ASC-US or LSIL
cytology) and the outcome3 (CIN2+ or CIN3+).
Methodology
Suppose there are K tests and I studies. Studies assessing two tests (k = 2) are called
‘two-arm’ studies while those with k > 2 are ‘multi-arm’ studies. For a certain study i,
let (Yi1k, Yi2k) denote the true positives and true negatives, (Ni1k, Ni2k) the diseased
and healthy individuals and (pii1k, pii2k) the ‘unobserved’ sensitivity and specificity
respectively with test k in study i. Given study-specific sensitivity and specificity, two
independent binomial distributions describe the distribution of true positives and true
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negatives among the diseased and the healthy individuals as follows;
Yijk | piijk, xi ∼ bin(piijk, Nijk), i = 1, . . . I, j = 1, 2, k = 1, . . . K, (1)
where xi generically denotes one or more covariates, possibly affecting piijk . In the
next section, we present the recently introduced contrast-based model4 followed by our
proposed arm-based model to estimate the mean as well as comparative measures of
sensitivity and specificity.
Contrast-based model
By taking diagnostic test TK as the baseline, Menten and Lessafre (2015)4 proposed the
following model,
logit(piijk) = θijk
θij1 = µij + (K − 1)×
δij1
K
−
δij2
K
−
δij3
K
− . . .
δij(k−1)
K
θij2 = µij −
δij1
K
+ (K − 1)×
δij2
K
−
δij3
K
− . . .
δij(k−1)
K
θijK = µij −
δij1
K
−
δij2
K
−
δij3
K
− . . .
δij(k−1)
K
with
(δi11, δi12, δi21, δi22, . . . , δi1(K−1), δi2(K−1)) ∼ N(νδ, Σ)
and
νδ = (νδ11, νδ21, νδ12, νδ22 . . . , νδ1(K−1), νδ2(K−1)) (2)
The νδ represents the average log odds ratio for sensitivity and specificity of the K - 1
tests compared to the baseline test TK . There are known difficulties in estimating the
variance-covariance matrix Σ since each sampled matrix should be positive-definite16.
The authors therefore recommend a diagonal or block diagonal variance-covariance
matrix Σ. While this reduces model complexity and difficulty in estimation, such a
covariance matrix accounts for the correlation between contrasts but ignores correlation
between sensitivity and specificity. Moreover, the model identification becomes difficult
as the number of tests included increases.
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The authors estimate the absolute accuracy of the tests from the estimated
logit−1(µjk) as follows
µj1 = logit
−1(E(µj)) +
K − 1
K
× νδj1 −
1
K
× νδj2 −
1
K
× νδj3 − . . . −
1
K
× νδj(K−1)
µj2 = logit
−1(E(µj)) −
1
K
× νδj1 +
K − 1
K
× νδj2 −
1
K
× νδj3 − . . . −
1
K
× νδj(K−1)
µj3 = logit
−1(E(µj)) −
1
K
× νδj1 −
1
K
× νδj2 +
K − 1
K
× νδj3 − . . . −
1
K
× νδj(K−1)
µjK = logit
−1(E(µj)) −
1
K
× νδj1 −
1
K
× νδj2 −
1
K
× νδj3 − . . . −
1
K
× νδj(K−1)
(3)
where logit−1(E(µj)) is the average probability of testing positive/negative. Equation 3
estimates the accuracy of tests for a hypothetical study with random-effects equal to zero
but not the meta-analytic estimates as will be explained in the next section.
Arm-based model
Consider a design where there is at least one test per study. The study serves as a
block where all diagnostic accuracy tests are hypothetically evaluated of which some are
missing. This modelling approach has potential gain in precision by borrowing strength
from studies with single tests as well as multi-arm studies. The proposed single-factor
design with repeated measures model is written as follows
logit(piijk) = µjk + ηij + δijk(
ηi1
ηi2
)
∼ N
((
0
0
)
,Σ
)
Σ =
[
σ21 ρσ1σ2
ρσ1σ2 σ
2
2
]
(δij1, δij1, . . . δijK) ∼ N(0, diag(τ2j )) (4)
where µ1k and µ2k are the mean sensitivity and specificity in a hypothetical study with
random-effects equal to zero respectively. ηij is the study effect for healthy individuals
(j = 1) or diseased individuals (j = 2) and represents the deviation of a particular study i
from the mean sensitivity (j=1) or specificity (j=2), inducing between-study correlation.
The study effects are assumed to be a random sample from a population of such effects.
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The between-study variability of sensitivity and specificity and the correlation thereof is
captured by the parameters σ21 , σ22 , and ρ respectively. δijk is the error associated with
the sensitivity (j=1) or specificity (j=2) of test k in the ith study. Conditional on study
i, the repeated measurements are independent with variance constant across studies such
that τ 2j = (τ2j1, . . . , τ2jK ) is a K dimensional vector of homogeneous variances.
In case τ2jk = τ2j (variances homogenous across tests), the shared random element ηij
within study i induce a non-negative correlation between any two test results k and k′
from healthy individuals (j = 1) or from diseased individuals (j = 2) equal to ρj = σ
2
j
σ2j+τ
2
j
(implying that a covariance matrix with compound symmetry). While it might seem
logical to expect and allow for similar correlation between any two sensitivities or
specificities in a given study, the variances τ2jk of different sensitivities or specificities
of the same study may be different. In such instances, the unstructured covariance matrix
is more appropriate as it allows varying variances between the tests (in which case τ 2j is
a K dimension vector of the unequal variances). The correlation between the kth and k′th
test result is then equal to ρ′jkk =
σ2j√
σ2
j
+τ2
jk
×(σ2
j
+τ2
jk′
)
. ρj or ρ
′
jkk is called the intra-study
correlation coefficient which also measures the proportion of the variability in logit(piijk)
that is accounted for by the between study variability. It takes the value 0 when σ2j = 0
(if study effects convey no information) and values close to 1 when σ2j is large relative to
τ2j and the studies are essentially all identical. When all components of τ 2j equal to zero,
the model reduces to fitting separate bivariate random-effect meta-analysis (BRMA)17;18
model for each test.
In essence, the model separates the variation in the studies into two components: the
within-study variation diag(τ2j ) referring to the variation in the repeated sampling of
the study results if they were replicated, and the between-study variation Σ referring to
variation in the studies true underlying effects.
The study-level covariate information is included in the linear predictor in Equation 4
as follows
logit(piijk) = µjk +
P∑
p=1
θpjkXpi + ηij + δijk (5)
where θpjk is the pth coefficients corresponding to the Xpi covariate in a hypothetical
study with random-effects equal to zero respectively. The population-averaged or the
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marginal sensitivity/specificity in the intercept-only model for test k is estimated as
E(piijk) = E(logit
−1(µjk + ηij + δijk))
=
∫
∞
−∞
logit−1(µjk + ηij + δijk) f(ηij) f(δijk) dηij dδijk. (6)
The relative sensitivity and specificity and other relative measures of test k (relative to
test k′, k 6= k′) are then estimated from the marginal sensitivity or specificity of test k
and k’.
In most practical situations, the mean structure is of primary interest and not the
covariance structure. Nonetheless, appropriate covariance modelling is critical in the
interpretation of the random variation in the data as well as obtaining valid model-
based inference for the mean structure. Compound symmetry assumes homogeneity of
variance and covariance and such restriction could invalidate inference for the mean
structure when the assumed covariance structure is misspecified19. When the primary
objective of the analysis is on estimating the marginal means of sensitivity and specificity,
the choice between compound symmetry and unstructured covariance structure is not
critical because the inference procedure for the marginal means are the same. Moreover,
over-parameterisation of the covariance structure might lead to inefficient estimation and
potentially poor assessment of standard errors of the marginal means20.
Ranking of the tests
While ranking of tests using rank probabilities and rankograms is an attractive feature of
univariate NMA, it is still a challenge to rank competing diagnostic tests especially when
a test does not outperform the others on both sensitivity and specificity. Consider the
diagnostic odds ratio (DOR)21 which is expressed in terms of sensitivity and specificity
as
DORk =
sensitivityk × specificityk
(1− sensitivityk)× (1− specificityk)
. (7)
and ranges from 0 to ∞ with: DORk > 1 or higher indicating better discriminatory
test performance, DORk = 1 indicating a test that does not discriminate between the
healthy and diseased, and DORk < 1 indicating an improper test. The DOR is a single
indicator combining information about sensitivity and specificity and is invariant of
disease prevalence. However, the measure cannot distinguish between tests with high
sensitivity but low specificity or vice-versa.
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Alternatively, the superiority of a diagnostic test could be quantified using a superiority
index introduced by Deutsch et al.22 expressed as
Sk =
2ak + ck
2bk + ck
, (8)
where ak is the number of tests to which test k is superior (higher sensitivity and
specificity), bk is the number of tests to which test k is inferior (lower sensitivity and
specificity), and ck the number of tests with equal performance as test k (equal sensitivity
and specificity). S ranges from 0 to ∞ with; S tending to ∞ and S tending to 0 as the
number of tests to which test k is superior and inferior increases respectively, and S
tending to 1 the more the tests are equal. Since the number of tests not comparable to
test k do not enter into the calculation of S the index for different tests may be based on
different sets of tests.
Missing data and exchangeability
In the models above, not all the studies provide estimates of all effects of interest because
some of the components of the vector Yij = (Yij1, . . . , YijK) are missing. The Yij
vector can be partitioned into the observed Yoij and the missing Ymij . For each component
of Yij let Rij denote a vector of missingness indicator with
Rijk =
{
1 if Yijk is observed,
0 otherwise.
The joint distribution of (Y, R) given the parameters (β, φ) is given by
p(yij , Rij |βj,φj) (9)
where φj contains the missingness paramaters and βj contains
(piij , Σ, ρ, σj , diag(τ j)). In a selection framework23;24 the joint distribution in
Equation 9 is factorised as
p(yij | βj),φj p(Rij | Yij , φj) = p(y
o
ij , y
m
ij | βj , φj)p(Rij | Y
o
ij , Y
m
ij , φj) (10)
where p(Rij | yoij , ymij , φj) describes the mechanism for data missingness. Assuming
that the probability of missingness is conditionally independent of the unobserved data
given the observed (so called missing at random (MAR)), the second part of Equation 10
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simplifies to
p(Rij | y
o
ij , y
m
ij , φj) = p(Rij | y
o
ij , φj). (11)
When the parameters βij and φij are distinct and functionally independent, the missing
data mechanism is ignorable and the Expression 11 can be dropped from the joint
distribution in Equation 9. Intergrating over the unknown missing values in the first part
of Equation 10 yields a marginal density with the observed information which is to be
evaluated ∫
p(yoij , y
m
ij | βj) dy
m
ij = p(y
o
ij | βj). (12)
Since the main objective is to be able to make valid and efficient inference about the
parameters of interest and not to estimate or predict the missing data, the ignorability
condition validates inference based on the observed data likelihood only. Conditional on
piijk the studies are assumed to be exchangeable. The observed information Yijk on a
given test/arm k generically represents a point estimate of piijk and contributes to the
estimation of the fixed effects µjk . At the second level of the hierarchy (Equation 3
and 6), exchangeable normal prior distributions with mean zero split the variability into
between- and within-study variability. The observed data in each study contributes to the
estimation of ηij while all the studies all-together contribute to the estimation of δijk
where δijk and ηij are considered independent samples from a population controlled by
the hyper-parameters Σ and τ2j which are estimated from the observed data. The hyper-
parameters also have exchangeable vague or non-informative prior distributions.
The exchangeability assumption is applied in both the CB and the AB models but in a
different manner. The CB model assumes exchangeability of tests contrasts (odds ratios)
across the studies while the AB assumes exchangeability of tests effects (means) across
the studies.
Prior distributions
We decompose the covariance matrix Σ into a variance and correlation matrix such that
Σ = diag(σ1, σ2)× Ω× diag(σ1, σ2), (13)
where
Ω =
[
1 ρ
ρ 1
]
.
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The model is completed by specifying vague priors on the mean, variance and correlation
parameters as follows
tanh−1(ρ), µjk ∼ N(0, 25)
τj , σj ∼ U(0, 5). (14)
Since it is not clear when certain choices of prior distributions are vague and non-
informative, it is necessary to vary the prior distribution and assess their influence on
the parameter estimates. The following prior distributions were also used as part of a
sensitivity analysis
ρ ∼ U(−1, 1)
τj , σj ∼ cauchy(0, 2.5). (15)
An alternative prior distribution for the correlation matrix Ω is the LKJ prior distribution
with shape parameter ν = 1 or ν = 225.
Ω ∼ LKJcorr(ν) ∝ det(Ω)ν−1 for ν ≥ 1, (16)
where ν controls the expected correlation with larger values favouring less correlation
and vice-versa. Other possible prior distributions for Σ are: the Inverse-Wishart
distribution having the advantage of computational convenience but being difficult
to interpret or the more relaxed scaled inverse Wishart which is a conjugate to the
multivariate normal making Gibbs sampling simpler26.
Implementation
The models are fitted in the Bayesian framework using Stan27, a probabilistic
programming language which has implemented Hamilton Monte Carlo (MHC) and No-
U-Turn sampler (NUTS)28 within R 3.2.329 using the rstan 2.8.2 package30. The Stan
code for the model is provided alongside the supplementary material. We run three chains
in parallel until there is convergence. Trace plots are used to visually check whether
the distributions of the three simulated chains mix properly and are stationary. For each
parameter, convergence is assessed by examining the potential scale reduction factor Rˆ,
the effective number of independent simulation draws (neff ) and the MCMC error. It is
common practice to run simulations until Rˆ is no greater than 1.1 for all the parameters.
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Since Markov chain simulations tend to be autocorrelated, neff is usually smaller
compared to the total number of draws. To reduce autocorrelation and consequently
increase neff , it is necessary to do thinning by keeping every nth (e.g. every 10th, 20th,
30th . . . ) draw and discarding the rest of the samples. Besides, thinning saves memory
especially when the total number of iterations is large.
Results
Figure 2 presents the study-specific sensitivity and specificity of all the eleven used to
detect CIN2+ in ASC-US triage from all available studies and from studies that evaluated
at least two tests one of them being test 1. We successively present the sensitivity
and specificity of the eleven tests in triage of ASC-US and LSIL for outcomes CIN2+
and CIN3+, in figures 3, 4 and 5 respectively. Representing the pooled sensitivity and
specificity, the black diamonds are estimated by the AB model from all the available
studies, the red diamond by the same model but from studies with at least two tests
with one of them being test 1 while the blue diamonds are estimated by the CB model
from studies with at least two tests with one of them being test 1. The vertical lines
represent the 95% credible intervals. In each instance, the studies included in estimating
the diagnostic accuracy estimates are in grey points underlying the diamonds. From
the study-specific grey points there was substantial variation in both sensitivity and
specificity between the studies and some studies had outlying values. It is also apparent
that the number of tests evaluated differed among studies (see also supplementary
material : Additional-tables.docx).
All available data (black diamonds)
Triage of women with ASC-US to detect CIN2+ According to figure 2, test 6 (Linear
Array) was the most sensitive (0.91[0.87, 0.94]) but among the least specific (0.44 [0.36,
0.51]) tests while test 10 (HPV Proofer) the least sensitive (0.68 [0.59, 0.76]) and the
most specific (0.79 [0.73, 0.84]) test.
Both the diagnostic odds ratio and superiority index in the supplementary material
(Results1.xlsx) indicate that test 9 (p16/Ki67) had the best discriminatory power with
a sensitivity of 0.84 [0.76, 0.91] and specificity of 0.74 [0.66, 0.81]. Compared to test 1
(HC2), tests 3 (LBC), 8 (p16) and 10 (HPV Proofer) were less sensitive but more specific,
while tests 9 (p16/Ki67) was equally as sensitive but more specific. All other tests had
similar sensitivity and specificity as test 1 (HC2) (see table 1).
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Figure 2. Plot of study-specific sensitivity (top) and specificity (bottom) in grey points and
their corresponding pooled (diamonds) estimates with their 95% credible intervals (vertical
lines) of tests1 detecting CIN2+3 in ASC-US2 triage. The black diamonds and vertical lines are
estimated by the AB model from all the available studies, the red by the same model but from
studies with at least two tests with one of them being test 1 while the blue are estimated by
the CB model from studies with at least two tests with one of them being test 1.
Triage of women with ASC-US to detect CIN3+ It can be seen in figure 3 that test
5 (Abbott RT PCR hrHPV) was the most sensitive (0.97 [0.89, 1.00]) but among least
specific (0.48 [0.35, 0.60]) tests. The diagnostic odds ratio and the superiority index
(see supplementary material :Results1.xlsx) indicate that test 9 (p16/Ki67) had the best
discriminatory power with sensitivity and specificity of 0.96 [0.85, 1.00] and 0.66 [0.53,
0.78] respectively.
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Table 1. Posterior relative sensitivity and specificity and the corresponding 95% credible
intervals of other tests relative to test 1 (HC2) in detecting CIN2+3 in ASC-US2 triage as
estimated by the AB model
Relative sensitivity Relative specificity
Label Index test Mean Lower Upper Mean Lower Upper
2 Conventional Cytology (CC) 0.83 0.73 0.91 1.08 0.93 1.24
3 Liquid-Based Cytology (LBC) 0.81 0.70 0.90 1.30 1.12 1.47
4 Non-Commercial PCR assays 0.96 0.90 1.02 1.02 0.87 1.18
5 Abbott RT PCR hrHPV 1.00 0.90 1.06 0.97 0.75 1.18
6 Linear Array 1.00 0.96 1.05 0.82 0.67 0.96
7 Cobas-4800 1.01 0.94 1.06 1.01 0.80 1.21
8 P16 0.89 0.81 0.95 1.32 1.19 1.44
9 P16/Ki67 0.93 0.84 1.00 1.39 1.22 1.54
10 HPV Proofer(mRNA) 0.75 0.65 0.84 1.48 1.36 1.59
11 APTIMA(mRNA) 0.97 0.91 1.02 1.14 1.00 1.26
Relative to test 1 (HC2), test 3 (LBC), 4 (Non-commercial PCR assays), 8 (p16) and
10 (HPV Proofer) were less sensitive but more specific while tests 2 (CC), 5 (Abbott RT
PCR hrHPV), 7 (Cobas-4800) were as sensitive and specific (see table 2).
Table 2. Posterior relative sensitivity and specificity and the corresponding 95% credible
interval of other tests relative to test 1 (HC2) in detecting CIN3+3 in ASC-US2 triage as
estimated by the AB model
Relative sensitivity Relative specificity
Label Index test Mean Lower Upper Mean Lower Upper
2 Conventional Cytology (CC) 0.79 0.29 1.06 1.17 0.62 1.65
3 Liquid-Based Cytology (LBC) 0.84 0.71 0.93 1.45 1.25 1.63
4 Non-Commercial PCR assays 0.83 0.70 0.95 1.13 0.83 1.43
5 Abbott RT PCR hrHPV 1.03 0.95 1.08 0.97 0.70 1.24
6 Linear Array 1.03 0.99 1.06 0.81 0.65 0.99
7 Cobas-4800 1.03 0.97 1.07 0.99 0.74 1.24
8 P16 0.87 0.79 0.94 1.34 1.14 1.51
9 P16/Ki67 1.03 0.91 1.08 1.34 1.08 1.60
10 HPV Proofer(mRNA) 0.87 0.77 0.95 1.59 1.43 1.74
11 APTIMA(mRNA) 0.99 0.94 1.03 1.15 1.02 1.28
Triage of women with LSIL to detect CIN2+ Figure 4 and the absolute diagnostic
estimates presented in the supplementary material (Results1.xlsx) show that test 1 (HC2)
was the most sensitive (0.94 [0.93, 0.95]) test but among the least specific (0.29 [0.27,
0.31]) tests while test 10 (HPV proofer) was the least sensitive (0.64 [0.54, 0.73]) and
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Figure 3. Plot of study-specific sensitivity (top) and specificity (bottom) in grey points and
their corresponding pooled (diamonds) estimates with their 95% credible intervals (vertical
lines) of tests1 detecting CIN3+3 in ASC-US triage2. The black diamonds and vertical lines
are estimated by the AB model from all the available studies, the red by the same model but
from studies with at least two tests with one of them being test 1 while the blue are estimated
by the CB model from studies with at least two tests with one of them being test 1.
the most specific (0.73 [0.67, 0.78]) test detecting CIN2+ in LSIL cytology. Both the
diagnostic odds ratio and superiority index presented in the supplementary material
(Results1.xlsx) indicate once more that test 9 (p16/Ki67) had the best discriminatory
power with an estimated sensitivity and specificity of 0.86 [0.79, 0.91] and 0.63 [0.57,
0.69].
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Figure 4. Plot of study-specific sensitivity (top) and specificity (bottom) in grey points and
their corresponding pooled (diamonds) estimates with their 95% credible intervals (vertical
lines) of tests1 detecting CIN2+3 in LSIL2 triage. The black diamonds and vertical lines are
estimated by the AB model from all the available studies, the red by the same model but from
studies with at least two tests with one of them being test 1 while the blue are estimated by
the CB model from studies with at least two tests with one of them being test 1.
Triage of women with LSIL to detect CIN3+ The forest plot presented in figure 5
(see also supplementary material: Results1.xlsx) shows that tests 5 (Abbott RT PCR
hrHPV) and 6 (Linear Array) were the most sensitive but among the least specific
tests in detecting CIN3+ in women with LSIL. The diagnostic odds ratio indicate that
test 5 (Abbott RT PCR hrHPV) had the best discriminatory power (sensitivity = 0.99
[0.96, 1.00], specificity = 0.28 [0.20, 0.37]) while test 9 (p16/Ki67) best discriminatory
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Table 3. Posterior relative sensitivity and specificity and the corresponding 95% credible
interval of other tests relative to test 1 (HC2) in detecting CIN2+2 in LSIL2 triage as estimated
by the AB model
Relative sensitivity Relative specificity
Label Index test Mean Lower Upper Mean Lower Upper
2 Conventional Cytology (CC) 0.86 0.72 0.96 1.50 1.15 1.90
3 Liquid-Based Cytology (LBC) 0.82 0.69 0.93 1.88 1.52 2.22
4 Non-Commercial PCR assays 0.87 0.77 0.95 1.26 0.95 1.59
5 Abbott RT PCR hrHPV 0.98 0.90 1.03 1.22 0.93 1.55
6 Linear Array 0.98 0.93 1.02 0.98 0.77 1.21
7 Cobas-4800 0.96 0.89 1.02 1.13 0.85 1.45
8 P16 0.83 0.76 0.89 2.07 1.84 2.30
9 P16/Ki67 0.91 0.84 0.96 2.18 1.91 2.42
10 HPV Proofer(mRNA) 0.68 0.58 0.78 2.49 2.24 2.74
11 APTIMA(mRNA) 0.95 0.89 0.99 1.43 1.23 1.64
test (sensitivity = 0.94 [0.88, 0.98], specificity = 0.45 [0.34, 0.56]) according to the
superiority index.
According to table 3 and 4 test 5 (Abbott RT PCR hrHPV), 6 (Linear Array) and 7
(Cobas-4800) were as sensitive and as specific while most of the rest of the tests were
less sensitive but more specific as test 1 (HC2) in detecting CIN2+ and CIN3+ in triage
of women with LSIL cytology.
Table 4. Posterior relative sensitivity and specificity and the corresponding 95% credible
interval of other tests relative to test 1 (HC2) in detecting CIN3+3 in LSIL2 triage as estimated
by the AB model
Relative sensitivity Relative specificity
Label Index test Mean Lower Upper Mean Lower Upper
2 Conventional Cytology (CC) 0.71 0.31 0.99 1.91 1.13 2.76
3 Liquid-Based Cytology (LBC) 0.85 0.71 0.94 2.07 1.62 2.48
4 Non-Commercial PCR assays 0.80 0.67 0.91 1.71 1.22 2.30
5 Abbott RT PCR hrHPV 1.03 0.99 1.05 1.11 0.79 1.50
6 Linear Array 1.03 1.00 1.05 0.90 0.63 1.19
7 Cobas-4800 0.99 0.94 1.03 1.14 0.80 1.54
8 P16 0.86 0.77 0.93 2.16 1.79 2.48
9 P16/Ki67 0.98 0.91 1.02 1.81 1.32 2.28
10 HPV Proofer(mRNA) 0.79 0.67 0.87 2.73 2.38 3.08
11 APTIMA(mRNA) 1.00 0.97 1.03 1.39 1.16 1.65
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Figure 5. Plot of study-specific sensitivity and specificity in grey points and their
corresponding marginal (black points) sensitivity and specificity with their 95% credible
intervals (vertical lines) of diagnostic tests1 detecting CIN3+3 in LSIL2 triage. The black
squares are estimated by the AB model from all the available studies (underlying in grey), the
black diamond by the same model but from studies with at least two tests with one of them
being test 1 while the black triangles are estimated by the CB model from studies with at least
two tests with one of them being test 1.
Variance Components The total variability in sensitivity (in the logit scale) from a
compound symmetry working variance-covariance structure ranged from 0.24 [0.04,
0.64] (see supplementary material: Additional-tables.xlsx) in tests used to detect CIN3+
in ASC-US triage to 0.66 [0.41, 1.04] in tests used to detect CIN2+ in LSIL triage. The
percentage of total variability in logit sensitivity attributable to between study variability
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ranged from 21.86% [0.01%, 81.19%] in tests used to detect CIN3+ in LSIL triage to
74.09% [22.51%, 99.57%] in tests used to detect CIN2+ in ASC-US triage.
Similarly for logit specificity, the total variability ranged from 0.39 [0.24, 0.61] in tests
used to detect CIN3+ in LSIL to 0.54 [0.40, 0.73] in tests detecting CIN2+ in ASC-US
triage. Of the total variability in logit specificitiy, as low as 59.09% [29.32%, 79.23%] in
tests used to detect CIN2+ in ASC-US triage and as high as 75.79% [59.18%, 88.14%]
in tests used to detect CIN2+ in LSIL triage was due to between study heterogeneity.
In other words, there was a stronger correlation between any two logit specificities in a
given study than between any two logit sensitivities.
There was in general negative but insignificant correlation between sensitivity and
specificity except among tests used to detect CIN2+ in LSIL triage group (ρ = -0.80
[-1.00, -0.41]). The insignificant correlation parameters suggest absence of overall study
effect in the respective data.
Sensitivity Analysis The sensitivity analysis did not highlight any particular change on
the mean structure for different priors of the variance-covariance parameters. Based on
the MCMC error sampling the variance-covariance Σ was better sampled and less auto-
correlated with LKJ and Cauchy distributions.
AB versus CB model (black and red vs. blue)
The data were re-analysed to compare the estimates from the AB and CB was performed.
Studies included in the re-analysis evaluated at least two tests with one of them being
test 1 (HC2) set as the common comparator (based on the high number of studies that
evaluated test 1 (HC2) besides any another test). Test 1 (HC2) was set as the comparator
because most of the studies evaluated it besides another diagnostic test. The network plot
of the studies included in the re-analyses is shown in figure 6.
A graphical summary of the results from the second and third analysis are presented in
figures 2, 3, 4 and 5 and represented by the red and blue diamonds respectively. Overall,
there are discrepancies between the locations of the black, red and blue diamonds.
Firstly, while the black and blue diamonds represent the marginal means, the blue
diamonds represent the accuracy estimate for a hypothetical study with random-effects
equal to zero. This explains why the black and red diamonds are closer while the blue
diamonds are more deviating.
Secondly, the location of the black diamonds is estimated from all available data,
including studies evaluating single tests while the location of the red and blue diamonds
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Figure 6. Network plot with studies that evaluated at least two tests1 with test 1 (HC2) as the
common comparator by triage2 group and outcome3 .
are determined by studies evaluating at least two studies with one of them being test
1 (HC2). As a consequence of the reduced number of studies, the credible intervals
presented in vertical lines are wider especially for the CB approach. As a cascade
effect, the ranking of the tests based on the DOR and the superiority also changes (see
supplementary material: Results1.xlsx vs. Results2.xlsx vs. Results3.xlsx).
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Discussion
In this paper, we propose a conceptually simple model to estimate sensitivity and
specificity of multiple tests within a network meta-analysis framework analogous to a
single-factor analysis of variance method with repeated measures.
The model is based on the assumption that all the tests were hypothetically used
but missing at random. When the mechanism of missing data is not a crucial aspect
of inference, models ignoring the missing value mechanism and only using the observed
data as the proposed model does provide valid answers under a missing at random (MAR)
process. In contrast to the CB model, the proposed AB model uses all available data in
line with principle of intention-to-treat (ITT)2. The missing ‘unobservable’ sensitivities
and specificities are parameters are estimated along with the other parameters in the
model based on the exchangeability assumption. The cost however is that the model
assumptions cannot be formally checked from the data under analysis.
When the data were never intended to be collected in the first place, the MAR
assumption has been shown to hold as is the case in diagnostic studies where older tests
become less used and new tests progressively more available with time31.
In the analysis, we included studies with at least one test. This is still acceptable
because such studies still provide partial information allowing estimation of the mean
and the variance-covariance parameters and only the study effects estimates might have
larger standard errors26.
The proposed AB model allows for easy estimation of the marginal means and
credible intervals for the intra-class correlation. Bayesian methods are known to be
computationally intensive but with efficient sampling algorithms such as Hamilton
Monte Carlo sampling implemented in Stan27 convergence to a stationary distribution is
accelerated even with poor initial values. Furthermore parallel chain processing greatly
reduces computational time.
With the logit transformation, it is assumed that the transformed data is approximately
normal with constant variance. For binary data as well as proportions, the mean and
variance depend on the underlying probability. Therefore, any factor affecting the
probability will change the mean and the variance. This implies that a linear model
where the predictors affect the mean but assume a constant variance will not be
adequate. Nonetheless, when the model for the mean is correct but the true distribution
is not normal, the maximum likelihood (ML) estimates of the model parameters will
be consistent but the standard errors will be incorrect32. An alternative to the logit
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transformation would be a variance stabilizing angular transformation; however the
variance stabilizing property of the transform depends on each n being large33.
The natural and optimal modelling approach would be to use the beta distribution.
This was the motivation behind our work on copula based bivariate beta distribution in
meta-analysis of diagnostic data 34;35. Our further research will focus on how different
mean and correlation structures are accommodated and modelled using the beta-binomial
distribution in network meta-analysis of diagnostic data.
There were discrepancies in identifying the best test between the DOR and the
superiority index. While the range of values estimated by the two measures range from 0
to infinity, the DOR yield larger values than the superiority index. From the full dataset,
the superiority index consistently identified test 9 (p16/Ki67) as the best test. From the
reduced data, the DOR identified tests with very low sensitivity but high specificity or
vice-versa as the best and in disagreement with the superiority index. This illustrates that
DOR cannot distinguish between tests with high sensitivity but low specificity or vice-
versa. In contrast, the superiority index gives more weight to tests performing relatively
well on both diagnostic accuracy measures and less weight on tests performing poorly
on both diagnostic measures or tests performing better on one measure but poorly on the
other22. Nonetheless, both measures do not allow to prioritise one parameter which may
be clinically appropriate.
Incoherence or inconsistency within NMA is a major concern where for the same
contrast, the direct and indirect evidence differ substantially. Lu and Ades (2006)36, Dias
et al. (2010)37 and Krahn et al.(2014)38, explain how to visualize, detect and handle
inconsistencies. Since the AB model implicitly assumes consistency, the methods used
to detect and quantify inconsistency in CB need not be used in the AB models.
For the AB models, Hong et al. (2015)39 measure inconsistency by data-driven
magnitude of bias, the discrepancy between observed and imputed treatment(test) effects
while Piepho (2014)40 classifies grouping of studies according to the set of tests included
and introduce an interaction term: designs by test, to represent inconsistency. We caution
against the grouping of studies into designs and including the interaction between designs
and test into the model as proposed by Piepho (2014)40 because the design variable is an
observational factor which will only complicate the ‘cause-and-effect’ inference on test
and design.
From our viewpoint, inconsistency/incoherence is a form of heterogeneity between
the studies which is often due to missing information in an outlying or influential study.
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In our model, the influence of the study on the mean is adequately captured by study-
effects and the fact that the model hypothetically allows any two tests to be compared
directly within each study makes inconsistency less an issue. That said, it is important
to assess and identify influence of certain observations on the marginal mean. Detection
of influential observations within the Bayesian framework is a computationally involved
exercise and still an active research area.
This article does not consider individual-level data for which the model adaptation
is automatic. Future research includes a study on impact of various aspects of data
missingness on the robustness of the models.
Conclusion
The proposed AB model contributes to the knowledge on methods used in systematic
reviews of diagnostic data in presence of more than two competing tests. The AB
model is more appealing than the CB model for meta-analyses of diagnostic studies
because it yields marginal means which are easily interpreted and uses all available
data. Furthermore, the model is superior since more general variance-covariance matrix
structures can be easily accommodated.
Notes
1. Tests labels: 1-HC2, 2-CC, 3-LBC, 4-Generic PCR, 5-Abbott RT PCR hrHPV, 6-Linear Array,
7-Cobas-4800, 8-p16, 9-p16/ki67, 10-HPV Proofer, 11-APTIMA.
2. ASC-US: atypical squamous cells of unspecified significance, LSIL :low-grade squamous
intraepithelial lesions, CIN: cervival intraepithelial neoplasia
3. CIN2+: cervival intraepithelial neoplasia of grade two or worse, CIN3+: cervival intraepithelial
neoplasia of grade three or worse,
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